Back to search results

Financial Navigation for Acute Myeloid Leukemia

This study, ONC-LEUK-2406, is looking at how financial support, called financial navigation, affects people with Acute Myeloid Leukemia (AML). AML is a type of cancer that starts in the bone marrow. The study wants to see if systematic financial navigation helps reduce the financial burden (financial toxicity) that often comes with cancer treatment. You would be between 18 and 64 years old and newly diagnosed with AML. Half of the participants will receive systematic financial navigation, where staff proactively screen for financial needs. The other half will have access to standard financial resources if they ask for them. The main goal is to measure your self-reported financial burden using a special questionnaire after six months. The study plans to enroll 120 people, but its current status is unclear.

Study design
This is an interventional study that will randomly assign participants to one of two groups: systematic financial navigation or standard care. It plans to enroll 120 participants.
What's involved
The study will assess your self-reported financial toxicity at 6 months after you join.
Compensation
Not stated in the trial record.
Follow-up
Your financial toxicity will be measured for six months after you are randomized into a group.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06945042

ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia

Recruiting
NAAges 18–64InterventionalSupportive care
Wake Forest University Health Sciences
~120 participants
Updated 2026-07-23 on ClinicalTrials.gov
What's tested:Arm AArm B

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Self-reported financial toxicity as assessed by the total score of the COmprehensive Score Financial Toxicity (COST) assessment tool at 6 months after enrollment.
Measured over From the date of randomization up until six months

Conditions

Acute Myeloid Leukemia

Explore related trials

Acute Myeloid Leukemia

Where it's being run

2 sites across 1 states
North Carolina2

Study leadership

  • Thomas Knight, MD · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences

Who to contact

Courtney Schepel
[email protected]
(980) 442-2327
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Self-reported financial toxicity as assessed by the total score of the COmprehensive Score Financial Toxicity (COST) assessment tool at 6 months after enrollment.From the date of randomization up until six months

    For each participant, the total score of the COST at the 6-month assessment will be calculated. The total score is informed by 11 questions, each assessed on a 5-point scale of numerical values ranging 0 to 4, and the total score may range from 0 to 44 (where the lower score, the worse the financial well-being of the participant). Data of COST assessments from all randomized participants will inform this intent-to-treat analysis comparing scores between the arms.